Catalog No.
DHK10004
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Target
TAG-72
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
TAG-72
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
H22, MDX-33, H52, Huh52, HCC49, HuCC49, CAS: 823788-82-5
Clone ID
HuCC49
TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225 Ac-Labeled DOTAylated-huCC49 Antibody, PMID: 32620701
Humanized Fluorescent Tumor-associated Glycoprotein-72 Antibody Selectively Labels Colon-cancer Liver Metastases in Orthotopic Mouse Models, PMID: 32871754
Humanized Anti-Tumor-Associated Glycoprotein-72 for Submillimeter Near-Infrared Detection of Colon Cancer in Metastatic Mouse Models, PMID: 32217350
A novel monoclonal antibody design for radioimmunotherapy, PMID: 14629823
A CDR-grafted (humanized) domain-deleted antitumor antibody, PMID: 10851481
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49, PMID: 8575795
Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies, PMID: 16221669
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region, PMID: 16248766
Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues, PMID: 14522015
Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts, PMID: 12804050
111 In-(1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaaetic acid)-anti–TAG-72 humanized C H 2 domain-deleted antibody, PMID: 20641320
Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody, PMID: 10541352
Targeting strategies for cancer radiotherapy, PMID: 10541342
Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts, PMID: 10541333
Radioiodinated anti-TAG-72 humanized C H 2 domain-deleted antibody, PMID: 20641585
Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging, PMID: 20006382
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49, PMID: 11255077
In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants, PMID: 14654532
Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies, PMID: 12215388
Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody, PMID: 16407221
Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute, PMID: 14513687
CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity, PMID: 10698310
Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes, PMID: 18309354
Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA), PMID: 10632041
For research use only. Not for human or drug use.
